Roze Joline F, Hoogendam Jacob P, van de Wetering Fleur T, Spijker René, Verleye Leen, Vlayen Joan, Veldhuis Wouter B, Scholten Rob Jpm, Zweemer Ronald P
Department of Gynaecological Oncology, UMC Utrecht Cancer Center, Utrecht, Netherlands, 3508 GA.
Cochrane Database Syst Rev. 2018 Oct 8;10(10):CD012567. doi: 10.1002/14651858.CD012567.pub2.
Ovarian cancer is the leading cause of death from gynaecological cancer in developed countries. Surgery and chemotherapy are considered its mainstay of treatment and the completeness of surgery is a major prognostic factor for survival in these women. Currently, computed tomography (CT) is used to preoperatively assess tumour resectability. If considered feasible, women will be scheduled for primary debulking surgery (i.e. surgical efforts to remove the bulk of tumour with the aim of leaving no visible (macroscopic) tumour). If primary debulking is not considered feasible (i.e. the tumour load is too extensive), women will receive neoadjuvant chemotherapy to reduce tumour load and subsequently undergo (interval) surgery. However, CT is imperfect in assessing tumour resectability, so additional imaging modalities can be considered to optimise treatment selection.
To assess the diagnostic accuracy of fluorodeoxyglucose-18 (FDG) PET/CT, conventional and diffusion-weighted (DW) MRI as replacement or add-on to abdominal CT, for assessing tumour resectability at primary debulking surgery in women with stage III to IV epithelial ovarian/fallopian tube/primary peritoneal cancer.
We searched MEDLINE and Embase (OVID) for potential eligible studies (1946 to 23 February 2017). Additionally, ClinicalTrials.gov, WHO-ICTRP and the reference list of all relevant studies were searched.
Diagnostic accuracy studies addressing the accuracy of preoperative FDG-PET/CT, conventional or DW-MRI on assessing tumour resectability in women with advanced stage (III to IV) epithelial ovarian/fallopian tube/primary peritoneal cancer who are scheduled to undergo primary debulking surgery.
Two authors independently screened titles and abstracts for relevance and inclusion, extracted data and performed methodological quality assessment using QUADAS-2. The limited number of studies did not permit meta-analyses.
Five studies (544 participants) were included in the analysis. All studies performed the index test as replacement of abdominal CT. Two studies (366 participants) addressed the accuracy of FDG-PET/CT for assessing incomplete debulking with residual disease of any size (> 0 cm) with sensitivities of 1.0 (95% CI 0.54 to 1.0) and 0.66 (95% CI 0.60 to 0.73) and specificities of 1.0 (95% CI 0.80 to 1.0) and 0.88 (95% CI 0.80 to 0.93), respectively (low- and moderate-certainty evidence). Three studies (178 participants) investigated MRI for different target conditions, of which two investigated DW-MRI and one conventional MRI. The first study showed that DW-MRI determines incomplete debulking with residual disease of any size with a sensitivity of 0.94 (95% CI 0.83 to 0.99) and a specificity of 0.98 (95% CI 0.88 to 1.00) (low- and moderate-certainty evidence). For abdominal CT, the sensitivity for assessing incomplete debulking was 0.66 (95% CI 0.52 to 0.78) and the specificity 0.77 (95% CI 0.63 to 0.87) (low- and low-certainty evidence). The second study reported a sensitivity of DW-MRI of 0.75 (95% CI 0.35 to 0.97) and a specificity of 0.96 (95% CI 0.80 to 1.00) (very low-certainty evidence) for assessing incomplete debulking with residual disease > 1 cm. In the last study, the sensitivity for assessing incomplete debulking with residual disease of > 2 cm on conventional MRI was 0.91 (95% CI 0.59 to 1.00) and the specificity 0.97 (95% CI 0.87 to 1.00) (very low-certainty evidence). Overall, the certainty of evidence was very low to moderate (according to GRADE), mainly due to small sample sizes and imprecision.
AUTHORS' CONCLUSIONS: Studies suggested a high specificity and moderate sensitivity for FDG-PET/CT and MRI to assess macroscopic incomplete debulking. However, the certainty of the evidence was insufficient to advise routine addition of FDG-PET/CT or MRI to clinical practice..In a research setting, adding an alternative imaging method could be considered for women identified as suitable for primary debulking by abdominal CT, in an attempt to filter out false-negatives (i.e. debulking, feasible based on abdominal CT, unfeasible at actual surgery).
在发达国家,卵巢癌是妇科癌症死亡的主要原因。手术和化疗被视为其主要治疗手段,手术的彻底性是这些女性生存的主要预后因素。目前,计算机断层扫描(CT)用于术前评估肿瘤的可切除性。如果认为可行,女性将被安排进行初次肿瘤细胞减灭术(即通过手术努力切除大部分肿瘤,目标是不留可见(宏观)肿瘤)。如果认为初次肿瘤细胞减灭术不可行(即肿瘤负荷过大),女性将接受新辅助化疗以降低肿瘤负荷,随后进行(间隔)手术。然而,CT在评估肿瘤可切除性方面并不完美,因此可以考虑使用其他成像方式来优化治疗选择。
评估氟脱氧葡萄糖-18(FDG)PET/CT、传统和扩散加权(DW)MRI作为腹部CT的替代或补充,用于评估Ⅲ至Ⅳ期上皮性卵巢癌/输卵管癌/原发性腹膜癌女性患者初次肿瘤细胞减灭术时肿瘤可切除性的诊断准确性。
我们检索了MEDLINE和Embase(OVID)以查找潜在的符合条件的研究(1946年至2017年2月23日)。此外,还检索了ClinicalTrials.gov、世界卫生组织国际临床试验注册平台(WHO-ICTRP)以及所有相关研究的参考文献列表。
针对术前FDG-PET/CT、传统或DW-MRI评估计划接受初次肿瘤细胞减灭术的晚期(Ⅲ至Ⅳ期)上皮性卵巢癌/输卵管癌/原发性腹膜癌女性患者肿瘤可切除性准确性的诊断准确性研究。
两位作者独立筛选标题和摘要以确定相关性和纳入情况,提取数据并使用QUADAS-2进行方法学质量评估。研究数量有限,无法进行荟萃分析。
分析纳入了5项研究(544名参与者)。所有研究均将索引测试作为腹部CT的替代方法。两项研究(366名参与者)探讨了FDG-PET/CT评估任何大小(>0 cm)残留疾病的不完全肿瘤细胞减灭的准确性,敏感性分别为1.0(95%CI 0.54至1.0)和0.66(95%CI 0.60至0.73),特异性分别为1.0(95%CI 0.80至1.0)和0.88(95%CI 0.80至0.93)(低确定性和中等确定性证据)。三项研究(178名参与者)针对不同目标情况研究了MRI,其中两项研究了DW-MRI,一项研究了传统MRI。第一项研究表明,DW-MRI确定任何大小残留疾病的不完全肿瘤细胞减灭的敏感性为0.94(95%CI 0.83至0.99),特异性为0.98(95%CI 0.88至1.00)(低确定性和中等确定性证据)。对于腹部CT,评估不完全肿瘤细胞减灭的敏感性为0.66(95%CI 0.52至0.78),特异性为0.77(95%CI 从0.63至0.87)(低确定性和低确定性证据)。第二项研究报告DW-MRI评估残留疾病>1 cm的不完全肿瘤细胞减灭的敏感性为0.75(95%CI 0.35至0.97),特异性为0.96(95%CI 0.80至1.00)(极低确定性证据)。在最后一项研究中,传统MRI评估残留疾病>2 cm的不完全肿瘤细胞减灭的敏感性为0.91(95%CI 0.59至1.00),特异性为0.97(95%CI 0.87至1.00)(极低确定性证据)。总体而言,证据的确定性非常低至中等(根据GRADE),主要是由于样本量小和不精确性。
研究表明,FDG-PET/CT和MRI评估宏观不完全肿瘤细胞减灭具有高特异性和中等敏感性。然而,证据的确定性不足以建议在临床实践中常规添加FDG-PET/CT或MRI。在研究环境中,对于经腹部CT确定适合初次肿瘤细胞减灭术的女性,可以考虑添加替代成像方法,以试图筛选出假阴性结果(即根据腹部CT认为肿瘤细胞减灭可行,但实际手术时不可行)。